{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:18:16Z","timestamp":1787062696852,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00836-5","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T19:43:14Z","timestamp":1759434194000},"page":"2737-2750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Effectiveness of Direct Oral Anticoagulants in Combination with Antiseizure Medications: Protocol for a Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-7544","authenticated-orcid":false,"given":"Kai Michael","family":"Schubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Zelano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Seiffge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Galovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. https:\/\/doi.org\/10.1161\/jaha.120.017559.","DOI":"10.1161\/jaha.120.017559"},{"issue":"2","key":"836_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2396987317705536","volume":"2","author":"M Holtkamp","year":"2017","unstructured":"Holtkamp M, Beghi E, Benninger F, et al. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. Eur Stroke J. 2017;2(2):103\u201315. https:\/\/doi.org\/10.1177\/2396987317705536.","journal-title":"Eur Stroke J"},{"issue":"4","key":"836_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40263-025-01163-x","volume":"39","author":"M Nei","year":"2025","unstructured":"Nei M, Ho J, Ho RT. Cardiovascular effects of antiseizure medications for epilepsy. CNS Drugs. 2025;39(4):383\u2013401. https:\/\/doi.org\/10.1007\/s40263-025-01163-x.","journal-title":"CNS Drugs"},{"issue":"6","key":"836_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526\u201336. https:\/\/doi.org\/10.1002\/cpt.2369.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"836_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/epd2.20069","volume":"25","author":"C Johannessen Landmark","year":"2023","unstructured":"Johannessen Landmark C, Eyal S, Burns ML, Franco V, Johannessen SI. Pharmacological aspects of antiseizure medications: from basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring. Epileptic Disord. 2023;25(4):454\u201371. https:\/\/doi.org\/10.1002\/epd2.20069.","journal-title":"Epileptic Disord"},{"issue":"5","key":"836_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-024-01077-0","volume":"38","author":"R Goldstein","year":"2024","unstructured":"Goldstein R, Rabkin N, Buchman N, et al. The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations. CNS Drugs. 2024;38(5):399\u2013408. https:\/\/doi.org\/10.1007\/s40263-024-01077-0.","journal-title":"CNS Drugs"},{"issue":"3","key":"836_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100137","volume":"7","author":"M Candeloro","year":"2023","unstructured":"Candeloro M, Carlin S, Shapiro MJ, Douketis JD. Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review. Res Pract Thromb Haemost. 2023;7(3):100137. https:\/\/doi.org\/10.1016\/j.rpth.2023.100137.","journal-title":"Res Pract Thromb Haemost"},{"key":"836_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01067","author":"A Galgani","year":"2018","unstructured":"Galgani A, Palleria C, Iannone LF, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Mini review. Front Neurol. 2018. https:\/\/doi.org\/10.3389\/fneur.2018.01067.","journal-title":"Front Neurol"},{"key":"836_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1505665","author":"Y-T Huang","year":"2025","unstructured":"Huang Y-T, Chen T-L, Huang Y-L, et al. Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation. Original Research. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1505665.","journal-title":"Front Pharmacol"},{"issue":"10","key":"836_CR10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin\u00a0K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065.","journal-title":"Europace"},{"issue":"8","key":"836_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaneurol.2024.2057","volume":"81","author":"EK Acton","year":"2024","unstructured":"Acton EK, Hennessy S, Gelfand MA, et al. Direct-acting oral anticoagulants and antiseizure medications for atrial fibrillation and epilepsy and risk of thromboembolic events. JAMA Neurol. 2024;81(8):835\u201344. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2057.","journal-title":"JAMA Neurol"},{"issue":"8","key":"836_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","volume":"9","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin\u00a0K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722\u201330. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad070.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"836_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40263-022-00971-9","volume":"36","author":"BY Ip","year":"2022","unstructured":"Ip BY, Ko H, Wong GLH, et al. Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis. CNS Drugs. 2022;36(12):1313\u201324. https:\/\/doi.org\/10.1007\/s40263-022-00971-9.","journal-title":"CNS Drugs"},{"key":"836_CR14","doi-asserted-by":"publisher","unstructured":"Abou Kaoud M, Nissan R, Segev A, Sabbag A, Orion D, Maor E. Ischemic stroke risk in patients on direct oral anticoagulants with levetiracetam: a pharmacovigilance study. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.08.21.23294397.","DOI":"10.1101\/2023.08.21.23294397"},{"issue":"3","key":"836_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjcvp\/pvz035","volume":"6","author":"CL Wang","year":"2020","unstructured":"Wang CL, Wu VC, Chang KH, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin\u00a0K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):147\u201354. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz035.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"836_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18039","author":"M Giustozzi","year":"2024","unstructured":"Giustozzi M, Calvello C, Eusebi P, et al. Safety and efficacy of concomitant treatment with non-vitamin\u00a0K antagonist oral anticoagulants and antiseizure medications: a propensity score matching cohort study. Epilepsia. 2024. https:\/\/doi.org\/10.1111\/epi.18039.","journal-title":"Epilepsia"},{"key":"836_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.588053","author":"C-J Ho","year":"2021","unstructured":"Ho C-J, Chen S-H, Lin C-H, Lu Y-T, Hsu C-W, Tsai M-H. Non-vitamin\u00a0K oral anticoagulants and anti-seizure medications: a retrospective cohort study. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2020.588053.","journal-title":"Front Neurol"},{"issue":"7","key":"836_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.06.002","volume":"46","author":"E Rota","year":"2024","unstructured":"Rota E, Immovilli P, Pappalardo I, et al. Direct oral anticoagulants and concomitant anti-seizure medications: a retrospective, case-control study in a real-world setting. Clin Ther. 2024;46(7):e26. https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.002.","journal-title":"Clin Ther"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.atherosclerosis.2018.11.009","volume":"280","author":"SPC Hsu","year":"2019","unstructured":"Hsu SPC, Yeh CC, Chou YC, et al. Stroke risk and outcomes in epilepsy patients: two retrospective cohort studies based on National Health Insurance in Taiwan. Atherosclerosis. 2019;280:147\u201354. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.009.","journal-title":"Atherosclerosis"},{"issue":"35","key":"836_CR20","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/eurheartj\/ehad523","volume":"44","author":"J Wang","year":"2023","unstructured":"Wang J, Huang P, Yu Q, et al. Epilepsy and long-term risk of arrhythmias. Eur Heart J. 2023;44(35):3374\u201382. https:\/\/doi.org\/10.1093\/eurheartj\/ehad523.","journal-title":"Eur Heart J"},{"key":"836_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107550","volume":"113","author":"EK Acton","year":"2020","unstructured":"Acton EK, Gelfand MA, Hennessy S, et al. Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010\u20132018. Epilepsy Behav. 2020;113:107550. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107550.","journal-title":"Epilepsy Behav"},{"key":"836_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"836_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. https:\/\/doi.org\/10.1136\/bmj.l6890.","journal-title":"BMJ"},{"issue":"10","key":"836_CR24","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1111\/bcp.14821","volume":"88","author":"BD Chapron","year":"2022","unstructured":"Chapron BD, Chapron A, Leeder JS. Recent advances in the ontogeny of drug disposition. Br J Clin Pharmacol. 2022;88(10):4267\u201384. https:\/\/doi.org\/10.1111\/bcp.14821.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"836_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"836_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00c5S U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03678.x.","journal-title":"J Thromb Haemost"},{"issue":"23","key":"836_CR27","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/circulationaha.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736\u201347. https:\/\/doi.org\/10.1161\/circulationaha.110.009449.","journal-title":"Circulation"},{"key":"836_CR28","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Version 6.4 ed. Cochrane; 2023. https:\/\/www.cochrane.org\/handbook. Accessed 31 July 2025."},{"key":"836_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jclinepi.2017.12.009","volume":"95","author":"W Hoffmann-E\u00dfer","year":"2018","unstructured":"Hoffmann-E\u00dfer W, Siering U, Neugebauer EAM, Lampert U, Eikermann M. Systematic review of current guideline appraisals performed with the Appraisal of Guidelines for Research & Evaluation II instrument\u2014a third of AGREE II users apply a cut-off for guideline quality. J Clin Epidemiol. 2018;95:120\u20137. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.12.009.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"836_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-7-32","volume":"7","author":"YK Loke","year":"2007","unstructured":"Loke YK, Price D, Herxheimer A, the Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7(1):32. https:\/\/doi.org\/10.1186\/1471-2288-7-32.","journal-title":"BMC Med Res Methodol"},{"key":"836_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"836_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/17425255.2025.2510302","volume":"21","author":"R Roberti","year":"2025","unstructured":"Roberti R, Riva A, Striano P, Russo E. Drug-drug interaction between anti-seizure medications in Dravet syndrome and Lennox-Gastaut syndrome. Expert Opin Drug Metab Toxicol. 2025;21(7):847\u201364. https:\/\/doi.org\/10.1080\/17425255.2025.2510302.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"836_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-82790-8","volume-title":"Antiseizure medication interactions: a clinical guide","author":"PN Patsalos","year":"2022","unstructured":"Patsalos PN. Antiseizure medication interactions: a clinical guide. 4th ed. Berlin: Springer; 2022.","edition":"4"},{"issue":"16","key":"836_CR34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657\u201365. https:\/\/doi.org\/10.1001\/jama.2015.3656.","journal-title":"JAMA"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00836-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:13Z","timestamp":1763376313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00836-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eugen Trinka is an Editorial Board member of\n                      Neurology and Therapy\n                      . Eugen Trinka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kai Michael Schubert, Johan Zelano, David J. Seiffge, Francesco Brigo, Nishant R. Mishra, Emilio Russo, and Marian Galovic declare no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this study involves a systematic review and meta-analysis of published data, including aggregate-level and potentially de-identified IPD, formal ethical approval is not required. No new data will be collected directly from participants. For the planned IPD meta-analysis, only anonymized data will be used, and all contributing centers will be asked to confirm that local data governance and ethical requirements have been met prior to data sharing. The research team will adhere to all relevant data protection standards and ethical guidelines for secondary data analysis. The IPD-MA results will be reported as a separate companion publication and used to refine the conclusions of the aggregate-data systematic review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The findings of this systematic review will be disseminated through publication in a peer-reviewed scientific journal and presentation at relevant international neurology, cardiology, and pharmacology conferences. Results will be communicated to clinical stakeholders, including neurologists, cardiologists, and general practitioners, to inform safer prescribing practices in patients requiring both DOAC and ASM therapy. The conclusions may also serve to support future updates to clinical guidelines and highlight key evidence gaps requiring further prospective or interventional research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dissemination"}}]}}